JP2004269361A - Growth hormone sectretomotory composition - Google Patents
Growth hormone sectretomotory composition Download PDFInfo
- Publication number
- JP2004269361A JP2004269361A JP2003057850A JP2003057850A JP2004269361A JP 2004269361 A JP2004269361 A JP 2004269361A JP 2003057850 A JP2003057850 A JP 2003057850A JP 2003057850 A JP2003057850 A JP 2003057850A JP 2004269361 A JP2004269361 A JP 2004269361A
- Authority
- JP
- Japan
- Prior art keywords
- gaba
- composition
- lactic acid
- growth hormone
- acid bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】
【発明の属する技術分野】
本発明は乳酸菌醗酵から生産されるγ―アミノ酪酸(GABA)を含有する成長ホルモン分泌促進組成物に関する。更に上記成長ホルモン分泌促進組成物を含有する食品及び化粧品に関する。
【0002】
【従来の技術】
成長ホルモン(growth hormone:以下GHと記す)は脳の視床下部で作られ、血液にのって全身に運ばれる。このホルモンは、生体内での成長を促す役割をすることが知られている。具体的には、筋肉を作り、骨を伸ばし、また体内の様々な化学反応を促進することが報告されている。実際成長ホルモンをヒトに注射すると、筋肉、骨格の増強、脂肪の減少、皮膚の若返り、免疫力の回復などの効果が認められている。
【0003】
しかしその反面、GHの注射は自己が持つGHの分泌力を低下させ、合成GHへの依存性を高めてしまう危険性が指摘されている為、投与は極限られた疾病時にしか使用されないのが現状である。
【0004】
一方、γ―アミノ酪酸(γ−aminobutyric acid:以下GABAと記す)はGHの分泌促進作用をもつことが報告されている(F.Cavagnini et al.,Acta Endocrinologica 1980,93,149−154)。本Cavagnini等の報告ではGABAを5gから18g摂取することで成長ホルモン分泌が促進される事を報告している。
【0005】
GABAは、近年発芽玄米などの流行により一般的に広く知られるようになったアミノ酸の一種であり、野菜、果物をはじめ発酵食品に至るまで自然界の動植物に幅広く含まれており、我々の食生活の中で通常摂取されている食品成分のひとつである。一方医薬効果も非常に高く、1日3gの摂取で頭部外傷後遺症に伴う諸症状(頭痛、頭重、昜疲労性、のぼせ感、耳鳴り、記憶障害、睡眠障害、意欲低下)に対して改善効果が認められている。従って、上記術のように健常人に対し1日3g以上もの高濃度GABAの摂取は、副作用も実際報告されているため現実的な量ではない。
【0006】
しかしGABAを実際に摂取できる量(10mgから3000mg)の投与では、顕著なGH分泌促進効果が期待できない。又GH由来の筋肉、骨格の増強、脂肪の減少などの生理効果も本摂取量では期待できない。
【0007】
一方バリン、ロイシン、イソロイシン、アルギニン、リジン、ヒスチジンなどもGH促進効果があることが報告されている。しかし、上記述の成長ホルモンの促進が報告されているアミノ酸も単独ではGABA同様高濃度摂取しなければ筋肉、骨格の増強などの生理効果まで期待できない。
【0008】
又バリン、ロイシン、イソロイシン、アルギニン、リジン、ヒスチジンのアミノ酸は、消化管並びに脳から吸収される際競合しあうため、上記述アミノ酸同士の組み合わせによる相乗効果は通常得られない。
【0009】
【発明が解決しようとする課題】
本発明の目的は、より生理効果の高いGH分泌促進組成物を提供することを目的とする。更にアミノ酸と乳酸菌発酵GABAと組み合わせることで、最も生理効果の高いGH分泌促進組成物を提供することを目的とする。
【0010】
【課題を解決するための手段】
本発明者等は鋭意検討した結果、純品GABAよりも乳酸菌発酵したGABAの方がより効果的にGHを上昇させることを見出した。
【0011】
又バリン、ロイシン、イソロイシン、アルギニン、リジン、ヒスチジンなどのアミノ酸は、いずれもGH分泌促進作用が報告されているが、通常消化管及び脳に取り込まれる際競合しあうため、組み合わせて摂取しても相乗効果は期待できない。しかし、驚くべきことに乳酸菌醗酵したGABAとバリン、ロイシン、イソロイシン、アルギニン、リジン、ヒスチジンの内1つ又は2つ以上との組み合わせは、拮抗することなくGH分泌を飛躍的に促進するといった相乗効果を初めて見出した。
【0012】
その結果、乳酸菌醗酵したGABAとバリン、ロイシン、イソロイシン、アルギニン、リジン、ヒスチジンの内1つ又は2つ以上との組み合わせにより、低濃度の摂取でも、蛋白合成能を向上することができた。故に本発明は、効果的に成長ホルモン分泌促進させる組成物を提供することにある。
【0013】
又本発明の食品及び化粧品は、前記成長ホルモン分泌促進組成物を含有することを特徴とする。
【0014】
本発明によれば、副作用の心配が全くなく、経口摂取によって筋肉、骨格の増強、脂肪の減少、皮膚の若返り、免疫力の回復などの生理効果が期待できる食品、及び化粧品を提供できる。
【0015】
【発明の実施の形態】
本発明の成長ホルモン分泌促進組成物は、GABAを含有する組成物である。
【0016】
本発明におけるGABAを含有する組成物とは、乳酸菌醗酵により生産されるGABAが望ましい。更に好ましくは、ラクトバチルス属の細菌から醗酵法で生産されるGABAのことであり、最も好ましいのはラクトバチルス ヒルガルディーK−3株の細菌から醗酵法で生産されるGABAである。
【0017】
上記述の乳酸菌醗酵した溶液は、適宜凍結乾燥やスプレードライにて乾燥し粉末化しても構わない。特に限定するものではないが、GABAの含有量は液状では5%〜30%であり、粉末状では10%〜90%である。
【0018】
上記術GABAの生理効果が期待できる1日当たりの有効摂取量は、10mg〜3000mgが好ましい。より好ましくは、50mg〜1000mgであり、更に好ましくは100mg〜500mgである。
【0019】
バリン、ロイシン、イソロイシン、アルギニン、リジン、ヒスチジンの内1つ又は2つ以上の物質を含有することを特徴とするGH分泌促進組成物とは、GABAと上記術アミノ酸の1つ又は2つ以上含有する複合組成物の事をいう。
【0020】
GH分泌促進組成物におけるバリン、ロイシン、イソロイシン、アルギニン、リジン、ヒスチジンの内1つ又は2つ以上アミノ酸の含有量は特に限定するものではないが、GH分泌促進組成物中10〜90%含まれる事が好ましい。より好ましくは60〜90%であり、更に好ましくは50〜90%である。
【0021】
本発明の食品及び化粧品は、上記述成長ホルモン分泌促進組成物を10mg〜5000mg含有することが好ましく、更に好ましくは100mg〜1000mgであり、最も好ましいのは50mg〜1000mgである。
【0022】
上記食品としては、特に制限はなく、例えば清涼飲料、スポーツ飲料、ヨーグルト、錠菓、顆粒品、チョコレート、ガム、スープ類、おかゆ、味噌などが挙げられる。
【0023】
上記化粧品としては、特に制限はなく、例えばクリーム、ローション、ジェルなどが挙げられる。
【0024】
【実施例】
以下、実施例を挙げて本発明を具体的に説明するが、本発明はこれらに限定されるものではない。
【0025】
実施例1
乳酸菌発酵GABAの調製
表1に示す割合で各成分を含有する発酵原料(pH5.0)50Lを、90℃で10分間加熱殺菌した後、キムチ由来の乳酸菌(ラクトバチルス ヒルガルディーK−3株(FERM P−18422))培養液50mLを接種し、30℃で3日間培養した。なお、発酵終了後の発酵液のGABA含量は51g/Lであった。この発酵液を90℃で10分間加熱殺菌した後、濾過助剤を加えてろ過し、得られたろ液を真空濃縮機で濃縮した後、凍結乾燥機にて乾燥し、粉砕して粉末化して乳酸菌発酵GABA組成物(GABA含量:65質量%)を得た。
【0026】
【表1】
【0027】
尚、GABA醗酵原料としてはグルタミン酸ソーダの他にグルタミン酸及び小麦グルテン、焼酎粕タンパク等をグルタミン酸原としても差し支えない。
【0028】
試験例1
GABA濃度の測定
GABA濃度は、以下の方法により測定した。
【0029】
各試料を0.2Nクエン酸ナトリウム緩衝液(pH2.2)で適宜希釈後、遠心分離又はろ過して固形物を除去し、測定試料とした。GABAの含量はアミノ酸含量測定の常法に従って高速液体クロマトグラフで以下の条件で分析した。
【0030】
使用機器:(株)島津製作所製の高速液体クロマトグラフLC−9A
分析用カラム:強酸性陽イオン交換樹脂カラムShin−pack Isc−07Na型
移動層緩衝液:(株)島津製作所製のアミノ酸移動層キットNa型
移動層流量:0.3ml/分
反応層1:0.04%次亜塩素酸ナトリウム溶液(pH10のホウ酸−炭酸緩衝液500mlに対して次亜塩素酸0.2ml)
反応層2:(株)島津製作所製のアミノ酸分析キットOPA試薬
反応層流量:0.2ml/分
検出:蛍光検出 Ex348nm、Em450nm
【0031】
実施例2
GABA投与によるGHへの影響
クリーン動物ラット、ウィスター系雄、4週齢を用い、GABAを投与した際のGHへの影響確認試験を行った。GABAサンプルとしては、GABA試薬(和光)と実施例1より得られた乳酸菌発酵GABA(ファーマギャバ50;(株)ファーマフーズ研究所)粉末を用いた。
【0032】
水に各GABAサンプルを懸濁させ、GABAとして100mg/100g体重になるよう経口ゾンデによる投与試験を以下の試験群で行った。
【0033】
1群 GABA試薬投与
2群 乳酸菌発酵GABA投与
【0034】
各サンプルを投与後、0分、30分、60分、120分後に屠殺し、血中GABA濃度の変動を調べた(データは省略)。その結果、血中のGABA濃度の推移はほぼ同様であった。
【0035】
更に同じ血液を用い、ラットGH量をELISA法(RAT GROWTH HORMONE ENZYME IMMUNOASSAY KIT:フナコシ)にて調べた。本結果を図1に示す。
【0036】
本結果より、GABA純品試薬と乳酸菌発酵GABA投与は、ほぼ同様の血中GABA濃度の推移が認められたにもかかわらず、興味深いことにGABA純品試薬より乳酸菌発酵GABAの群の方がGHの分泌促進効果が認められた。
【0037】
実施例3
GABA及びその他アミノ酸との組み合わせ投与によるGHへの影響
クリーン動物ラット、ウィスター系雄、4週齢を用い、GABA及びバリン、ロイシン、イソロイシン、アルギニン、リジン、ヒスチジンの内1つ又は2つ以上アミノ酸を同時に投与した際のGHへの影響確認試験を行った。GABAサンプルとしては、乳酸菌発酵GABA(ファーマギャバ50;(株)ファーマフーズ研究所)粉末を用いた。CMC水に各サンプルを懸濁させ、GABAとして100mg/100g体重になるよう経口ゾンデによる投与試験を以下の試験群で行った。更にバリン:ロイシン:イソロイシンは1:2:1になる様混合し、分岐鎖アミノ酸混合物(以下BCAAと記す)とし、混合物として100mg/100g体重になるよう経口ゾンデによる投与試験を以下の試験群で行った。アルギニンも100mg/100g体重になるよう投与した。
【0038】
1群 水投与(コントロール)
2群 乳酸菌発酵GABA投与(GABA)
3群 分岐鎖アミノ酸混合物投与(BCAA)
4群 アルギニン投与(Arg)
5群 分岐鎖アミノ酸投与+乳酸菌発酵GABA投与(BCAA+GABA)
6群 分岐鎖アミノ酸投与+アルギニン投与(BCAA+Arg)
【0039】
各群経時的に0分、30分後に屠殺し、血中のGH量を実施例2同様ELISA法にて分析した。その結果を図2に示す。
【0040】
更に同様の試験をリジン、ヒスチジンについても実施した(データは省略)。
【0041】
本結果より、GABA、分岐鎖アミノ酸、アルギニン、リジン、ヒスチジンは、GHの分泌を促進することが示された。しかし、GABA以外のアミノ酸の組み合わせは、逆にGHの分泌を抑制する経口が認められた。しかし、GABAとそれ以外のアミノ酸との組み合わせは、相乗効果をもたらすことが本試験により示された。
【0042】
実施例4
GABA及びその他アミノ酸との組み合わせ投与によるRNAへの影響
【0043】
蛋白合成能の指標として、肝臓中のRNA量をPCR法(関谷ら、『PCR最前線』1996年)により測定した。
【0044】
試験は実施例3で得られた肝臓を用いて分析を行った。結果を図3に示す。
【0045】
更に同様の試験をリジン、ヒスチジンについても実施した(データは省略)。
【0046】
以上の結果から、肝臓中のRNA量は各群ほとんど差が認められなかったが、興味深いことに、唯一BCAAと乳酸菌発酵GABAを組み合わせた群において、肝臓中のRNA量の増加が認められた。
【0047】
実施例4
以下特に限定するものではないが、本発明の成長ホルモン分泌促進組成物を含有する食品及び化粧品の処方例を挙げる。
【0048】
(1)顆粒状食品の処方例
還元麦芽糖 71mg
結晶セルロ−ス 70mg
ショ糖エステル 9mg
本発明組成物 200mg
(GABAとして50mg、BCAAとして100mg含有)
【0049】
(2)化粧品の処方例
ローション 1000ml
本発明組成物 200mg
(GABAとして50mg、BCAAとして100mg含有)
【0050】
【発明の効果】
以上説明した様に本発明によれば、安全な適切量の経口摂取によって筋肉、骨格の増強、脂肪の減少、皮膚の若返り、免疫力の回復などの生理効果が期待できる食品及び化粧品を提供でき、本発明の産業的利用価値は非常に大きい。
【図面の簡単な説明】
【図1】ラットの血中GH濃度の経時変化を示す図である。
【図2】ラットの血中GHの変動を示す図である。
【図3】ラット肝臓中mRNA量の変動を示す図である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a growth hormone secretion promoting composition containing γ-aminobutyric acid (GABA) produced from lactic acid bacteria fermentation. Furthermore, it is related with the foodstuff and cosmetics containing the said growth hormone secretion promoting composition.
[0002]
[Prior art]
Growth hormone (hereinafter referred to as GH) is produced in the hypothalamus of the brain and is carried throughout the body on blood. This hormone is known to play a role in promoting growth in vivo. Specifically, it has been reported that it creates muscles, stretches bones, and promotes various chemical reactions in the body. In fact, when humans are injected with growth hormone, effects such as muscle and skeletal enhancement, fat loss, skin rejuvenation, and recovery of immunity have been observed.
[0003]
However, on the other hand, the injection of GH decreases the secretory power of GH and increases the dependence on synthetic GH. Therefore, administration can be used only in limited diseases. Currently.
[0004]
On the other hand, γ-aminobutyric acid (γ-aminobutyric acid: hereinafter referred to as GABA) has been reported to have a GH secretion promoting action (F. Cavagnini et al., Acta Endocrinolologica 1980, 93, 149-154). In this report of Cavagnini et al., It is reported that growth hormone secretion is promoted by ingesting 5 to 18 g of GABA.
[0005]
GABA is a kind of amino acid that has become widely known in recent years due to the epidemic of germinated brown rice, and is widely contained in natural animals and plants from vegetables and fruits to fermented foods. It is one of the food ingredients that are usually ingested. On the other hand, the medical effect is also very high. Ingestion of 3 g per day improves various symptoms associated with sequelae of head injury (headache, head weight, fatigue, hot flashes, tinnitus, memory loss, sleep disorder, decreased motivation). Is allowed. Therefore, intake of high concentration GABA of 3 g or more per day for a healthy person as described above is not a realistic amount because side effects have been actually reported.
[0006]
However, a significant GH secretion promoting effect cannot be expected by administration of an amount (10 mg to 3000 mg) in which GABA can actually be taken. Physiological effects such as GH-derived muscle, skeletal enhancement, and fat reduction cannot be expected with this intake.
[0007]
On the other hand, valine, leucine, isoleucine, arginine, lysine, histidine and the like have also been reported to have a GH promoting effect. However, the above-mentioned amino acids that have been reported to promote growth hormone alone cannot be expected to have physiological effects such as muscle and skeletal enhancement unless they are ingested at a high concentration like GABA.
[0008]
In addition, since amino acids of valine, leucine, isoleucine, arginine, lysine and histidine compete when absorbed from the digestive tract and brain, a synergistic effect due to the combination of the above-mentioned amino acids is usually not obtained.
[0009]
[Problems to be solved by the invention]
An object of the present invention is to provide a GH secretion promoting composition having a higher physiological effect. Furthermore, it aims at providing the GH secretion promotion composition with the highest physiological effect by combining with an amino acid and lactic acid bacteria fermentation GABA.
[0010]
[Means for Solving the Problems]
As a result of intensive studies, the present inventors have found that GABA fermented with lactic acid bacteria increases GH more effectively than pure GABA.
[0011]
In addition, amino acids such as valine, leucine, isoleucine, arginine, lysine, and histidine have been reported to promote GH secretion, but they usually compete when taken into the digestive tract and brain, so they can be taken in combination. Synergistic effects cannot be expected. However, surprisingly, the combination of GABA fermented with lactic acid bacteria and one or more of valine, leucine, isoleucine, arginine, lysine and histidine dramatically increases GH secretion without antagonism. For the first time.
[0012]
As a result, it was possible to improve the protein synthesis ability even at low concentrations by combining lactic acid bacteria fermented GABA with one or more of valine, leucine, isoleucine, arginine, lysine and histidine. Therefore, this invention is providing the composition which promotes growth hormone secretion effectively.
[0013]
Moreover, the food and cosmetics of this invention are characterized by containing the said growth hormone secretion promoting composition.
[0014]
According to the present invention, it is possible to provide foods and cosmetics that can be expected to have physiological effects such as muscle, skeletal enhancement, fat loss, skin rejuvenation, and recovery of immunity without any side effects.
[0015]
DETAILED DESCRIPTION OF THE INVENTION
The growth hormone secretion promoting composition of the present invention is a composition containing GABA.
[0016]
The GABA-containing composition in the present invention is preferably GABA produced by lactic acid bacteria fermentation. More preferably, it is GABA produced by a fermentation method from a bacterium belonging to the genus Lactobacillus, and the most preferred is GABA produced by a fermentation method from a bacterium of Lactobacillus hilgardy K-3 strain.
[0017]
The lactic acid bacteria fermented solution described above may be appropriately dried by lyophilization or spray drying and powdered. Although not particularly limited, the GABA content is 5% to 30% in a liquid state and 10% to 90% in a powder form.
[0018]
The effective daily intake for which the physiological effect of the above-mentioned surgical GABA can be expected is preferably 10 mg to 3000 mg. More preferably, it is 50 mg-1000 mg, More preferably, it is 100 mg-500 mg.
[0019]
A GH secretion-promoting composition containing one or more substances of valine, leucine, isoleucine, arginine, lysine and histidine includes GABA and one or more of the above-mentioned surgical amino acids. It refers to a composite composition.
[0020]
The content of one or more amino acids among valine, leucine, isoleucine, arginine, lysine, and histidine in the GH secretion promoting composition is not particularly limited, but is included in the GH secretion promoting composition in an amount of 10 to 90%. Things are preferable. More preferably, it is 60-90%, More preferably, it is 50-90%.
[0021]
The food and cosmetics of the present invention preferably contain 10 mg to 5000 mg of the growth hormone secretion promoting composition described above, more preferably 100 mg to 1000 mg, and most preferably 50 mg to 1000 mg.
[0022]
There is no restriction | limiting in particular as said foodstuff, For example, a soft drink, a sports drink, a yoghurt, a tablet confectionery, a granule, chocolate, gum, soups, porridge, miso, etc. are mentioned.
[0023]
There is no restriction | limiting in particular as said cosmetics, For example, a cream, a lotion, a gel etc. are mentioned.
[0024]
【Example】
EXAMPLES Hereinafter, the present invention will be specifically described with reference to examples, but the present invention is not limited thereto.
[0025]
Example 1
Preparation of Lactobacillus Fermentation GABA 50 L of fermentation raw material (pH 5.0) containing each component in the proportions shown in Table 1 was heat sterilized at 90 ° C. for 10 minutes, and then kimchi-derived lactic acid bacteria (Lactobacillus hilgardi K-3 strain (FERM) P-18422)) 50 mL of culture solution was inoculated and cultured at 30 ° C. for 3 days. In addition, the GABA content of the fermented liquid after completion | finish of fermentation was 51 g / L. This fermented liquid is sterilized by heating at 90 ° C. for 10 minutes, and then filtered with a filter aid. The obtained filtrate is concentrated with a vacuum concentrator, then dried with a freeze dryer, pulverized and powdered. A lactic acid bacteria fermentation GABA composition (GABA content: 65% by mass) was obtained.
[0026]
[Table 1]
[0027]
In addition, as a GABA fermentation raw material, glutamic acid, wheat gluten, shochu protein, etc. may be used as the glutamic acid source in addition to sodium glutamate.
[0028]
Test example 1
Measurement of GABA concentration GABA concentration was measured by the following method.
[0029]
Each sample was appropriately diluted with 0.2N sodium citrate buffer (pH 2.2), and then centrifuged or filtered to remove solids, thereby preparing a measurement sample. The GABA content was analyzed by a high performance liquid chromatograph under the following conditions according to a conventional method for measuring amino acid content.
[0030]
Equipment used: High performance liquid chromatograph LC-9A manufactured by Shimadzu Corporation
Column for analysis: Strong acid cation exchange resin column Shin-pack Isc-07Na type moving bed buffer solution: amino acid moving bed kit manufactured by Shimadzu Corporation Na type moving bed flow rate: 0.3 ml / min reaction layer 1: 0 0.04% sodium hypochlorite solution (0.2 ml of hypochlorous acid per 500 ml of boric acid-carbonate buffer at pH 10)
Reaction layer 2: Amino acid analysis kit OPA reagent reaction layer manufactured by Shimadzu Corporation Flow rate: 0.2 ml / min Detection: fluorescence detection Ex 348 nm, Em 450 nm
[0031]
Example 2
Influence on GH by GABA administration A test for confirming the influence on GH when GABA was administered was conducted using clean animal rats, Wistar males, and 4 weeks old. As the GABA sample, GABA reagent (Wako) and lactic acid bacteria fermentation GABA (
[0032]
Each GABA sample was suspended in water, and an administration test using an oral sonde was conducted in the following test groups so that the body weight was 100 mg / 100 g body weight as GABA.
[0033]
Group 1 GABA
Each sample was sacrificed 0 minutes, 30 minutes, 60 minutes, and 120 minutes after administration, and the change in blood GABA concentration was examined (data not shown). As a result, the transition of GABA concentration in blood was almost the same.
[0035]
Furthermore, using the same blood, the amount of rat GH was examined by ELISA (RAT GROWTH HORMONE ENZYME IMMUNOASSAY KIT: Funakoshi). The results are shown in FIG.
[0036]
From these results, it can be seen that the GABA pure GABA reagent and lactic acid bacteria fermented GABA administration were interesting in that the lactic acid bacteria fermented GABA group was more GH than the GABA pure GA reagent, despite the similar changes in blood GABA concentration. Secretion promoting effect was observed.
[0037]
Example 3
Effects on GH by combination administration with GABA and other amino acids Using clean animal rats, Wistar male, 4 weeks old, GABA and one or more amino acids of valine, leucine, isoleucine, arginine, lysine, histidine A test for confirming the effect on GH when administered simultaneously was conducted. As a GABA sample, lactic acid bacteria fermentation GABA (
[0038]
Group 1 water administration (control)
Group 4 Arginine administration (Arg)
Group 5 administration of branched chain amino acids + administration of lactic acid bacteria fermentation GABA (BCAA + GABA)
Group 6 Branched chain amino acid administration + Arginine administration (BCAA + Arg)
[0039]
Each group was sacrificed after 0 minutes and 30 minutes over time, and the amount of GH in the blood was analyzed by ELISA as in Example 2. The result is shown in FIG.
[0040]
Further, the same test was conducted for lysine and histidine (data not shown).
[0041]
From these results, it was shown that GABA, branched chain amino acids, arginine, lysine and histidine promote GH secretion. However, the combination of amino acids other than GABA, on the contrary, was observed to suppress oral secretion of GH. However, this study has shown that the combination of GABA and other amino acids provides a synergistic effect.
[0042]
Example 4
Effects on RNA by combination administration with GABA and other amino acids
As an index of protein synthesis ability, the amount of RNA in the liver was measured by the PCR method (Sekiya et al., “PCR Frontline” 1996).
[0044]
The test was performed using the liver obtained in Example 3. The results are shown in FIG.
[0045]
Further, the same test was conducted for lysine and histidine (data not shown).
[0046]
From the above results, there was almost no difference in the amount of RNA in the liver in each group, but it was interesting that an increase in the amount of RNA in the liver was observed only in the group combining BCAA and lactic acid bacteria fermentation GABA.
[0047]
Example 4
Although it does not specifically limit below, the formulation example of the foodstuffs and cosmetics containing the growth hormone secretion promotion composition of this invention is given.
[0048]
(1) Granular food formulation example Reduced maltose 71 mg
Crystal cellulose 70mg
Sucrose ester 9mg
200 mg of the composition of the present invention
(50mg as GABA, 100mg as BCAA)
[0049]
(2) Formulation example for cosmetics Lotion 1000ml
200 mg of the composition of the present invention
(50mg as GABA, 100mg as BCAA)
[0050]
【The invention's effect】
As described above, according to the present invention, it is possible to provide foods and cosmetics that can be expected to have physiological effects such as muscle, skeletal enhancement, fat reduction, skin rejuvenation, and recovery of immunity by ingesting a safe and appropriate amount. The industrial utility value of the present invention is very large.
[Brief description of the drawings]
FIG. 1 is a graph showing changes in blood GH concentration in rats over time.
FIG. 2 is a graph showing fluctuations in blood GH in rats.
FIG. 3 shows changes in the amount of mRNA in rat liver.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003057850A JP4596304B2 (en) | 2003-03-04 | 2003-03-04 | Growth hormone secretion promoting composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003057850A JP4596304B2 (en) | 2003-03-04 | 2003-03-04 | Growth hormone secretion promoting composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004269361A true JP2004269361A (en) | 2004-09-30 |
JP4596304B2 JP4596304B2 (en) | 2010-12-08 |
Family
ID=33121109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003057850A Expired - Lifetime JP4596304B2 (en) | 2003-03-04 | 2003-03-04 | Growth hormone secretion promoting composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4596304B2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006061088A (en) * | 2004-08-27 | 2006-03-09 | Pharma Foods International Co Ltd | Concentration power-improving drink or food |
WO2006041158A1 (en) * | 2004-10-14 | 2006-04-20 | Daikin Industries, Ltd. | Method for modifying the ambience, and spray liquid and sprayer used in the method |
JP2006137748A (en) * | 2004-10-14 | 2006-06-01 | Daikin Ind Ltd | Atmosphere alteration method, and air spray and spray device used therefor |
JP2007056032A (en) * | 2004-10-14 | 2007-03-08 | Daikin Ind Ltd | Spraying apparatus |
WO2007086565A1 (en) * | 2006-01-30 | 2007-08-02 | Ajinomoto Co., Inc. | Growth hormone secretion regulator |
WO2007108071A1 (en) * | 2006-03-17 | 2007-09-27 | Pharma Foods International Co., Ltd. | Antistress composition and food and drink containing the same |
WO2007119684A1 (en) * | 2006-04-13 | 2007-10-25 | Daikin Industries, Ltd. | Spraying agent |
CN100386075C (en) * | 2005-11-18 | 2008-05-07 | 吴福同 | Medicine capable of promoting height elevation and formulation thereof |
JP2009501160A (en) * | 2005-07-07 | 2009-01-15 | ドゥーサン コーポレーション | Yaenari lactic acid bacteria culture, production method thereof, and cosmetic composition containing the culture |
JP2009045034A (en) * | 2007-08-22 | 2009-03-05 | Japan Tobacco Inc | Durability improver and durability improver-blended foodstuff |
JP2010053120A (en) * | 2008-07-28 | 2010-03-11 | Q P Corp | Skin improvement agent for oral, food containing the same, and method for improving skin |
JP2010533487A (en) * | 2007-07-17 | 2010-10-28 | ジュリアーニ ソシエタ ペル アチオニ | Method for preparing γ-aminobutyric acid (GABA) by using lactic acid bacteria (LAB) for surplus products in the agricultural and food industries |
JP2011132161A (en) * | 2009-12-24 | 2011-07-07 | Lion Corp | Growth hormone secretion promoter |
WO2012121140A1 (en) | 2011-03-04 | 2012-09-13 | ライオン株式会社 | Growth hormone secretion promoter |
JP2014047168A (en) * | 2012-08-31 | 2014-03-17 | Lion Corp | Growth hormone secretion promoter |
CN103808931A (en) * | 2012-11-06 | 2014-05-21 | 江苏维赛科技生物发展有限公司 | Enzyme linked immunosorbent assay kit for detecting sulfadiazine and detection method thereof |
KR101501328B1 (en) * | 2011-12-28 | 2015-03-18 | 동의대학교 산학협력단 | Skin care Composition |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240165171A1 (en) * | 2021-03-26 | 2024-05-23 | Seoul National University R&Db Foundation | Composition for enhancing physiological efficacy of lactic acid bacteria |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5826726B2 (en) * | 1975-06-13 | 1983-06-04 | カネボウ株式会社 | Keshiyouriyo |
JPH07227245A (en) * | 1994-02-18 | 1995-08-29 | Kyoto Pref Gov | Production of fermented food product |
JP2000014356A (en) * | 1998-04-27 | 2000-01-18 | Yakult Honsha Co Ltd | Production of gaba-containing beverage and food product |
WO2000064283A1 (en) * | 1999-04-27 | 2000-11-02 | International Health Products And Services Ltd. | Supplement for restoring growth hormone levels |
JP2001505590A (en) * | 1997-09-19 | 2001-04-24 | イー―エル マネージメント コーポレイション | Compositions and methods for reducing skin tingling |
JP2004187501A (en) * | 2002-10-15 | 2004-07-08 | Marukome Kk | Food material highly containing gamma-aminobutyric acid and method for producing the same |
-
2003
- 2003-03-04 JP JP2003057850A patent/JP4596304B2/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5826726B2 (en) * | 1975-06-13 | 1983-06-04 | カネボウ株式会社 | Keshiyouriyo |
JPH07227245A (en) * | 1994-02-18 | 1995-08-29 | Kyoto Pref Gov | Production of fermented food product |
JP2001505590A (en) * | 1997-09-19 | 2001-04-24 | イー―エル マネージメント コーポレイション | Compositions and methods for reducing skin tingling |
JP2000014356A (en) * | 1998-04-27 | 2000-01-18 | Yakult Honsha Co Ltd | Production of gaba-containing beverage and food product |
WO2000064283A1 (en) * | 1999-04-27 | 2000-11-02 | International Health Products And Services Ltd. | Supplement for restoring growth hormone levels |
JP2004187501A (en) * | 2002-10-15 | 2004-07-08 | Marukome Kk | Food material highly containing gamma-aminobutyric acid and method for producing the same |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006061088A (en) * | 2004-08-27 | 2006-03-09 | Pharma Foods International Co Ltd | Concentration power-improving drink or food |
AU2005292853B2 (en) * | 2004-10-14 | 2009-08-20 | Daikin Industries, Ltd. | Atmosphere modifying method and spray agent and spray device used in the same |
WO2006041158A1 (en) * | 2004-10-14 | 2006-04-20 | Daikin Industries, Ltd. | Method for modifying the ambience, and spray liquid and sprayer used in the method |
JP2006137748A (en) * | 2004-10-14 | 2006-06-01 | Daikin Ind Ltd | Atmosphere alteration method, and air spray and spray device used therefor |
JP2007056032A (en) * | 2004-10-14 | 2007-03-08 | Daikin Ind Ltd | Spraying apparatus |
AU2005292853C1 (en) * | 2004-10-14 | 2010-08-05 | Daikin Industries, Ltd. | Atmosphere modifying method and spray agent and spray device used in the same |
JP2009501160A (en) * | 2005-07-07 | 2009-01-15 | ドゥーサン コーポレーション | Yaenari lactic acid bacteria culture, production method thereof, and cosmetic composition containing the culture |
CN100386075C (en) * | 2005-11-18 | 2008-05-07 | 吴福同 | Medicine capable of promoting height elevation and formulation thereof |
WO2007086565A1 (en) * | 2006-01-30 | 2007-08-02 | Ajinomoto Co., Inc. | Growth hormone secretion regulator |
WO2007108071A1 (en) * | 2006-03-17 | 2007-09-27 | Pharma Foods International Co., Ltd. | Antistress composition and food and drink containing the same |
WO2007119684A1 (en) * | 2006-04-13 | 2007-10-25 | Daikin Industries, Ltd. | Spraying agent |
JP2010533487A (en) * | 2007-07-17 | 2010-10-28 | ジュリアーニ ソシエタ ペル アチオニ | Method for preparing γ-aminobutyric acid (GABA) by using lactic acid bacteria (LAB) for surplus products in the agricultural and food industries |
JP2009045034A (en) * | 2007-08-22 | 2009-03-05 | Japan Tobacco Inc | Durability improver and durability improver-blended foodstuff |
JP2010053120A (en) * | 2008-07-28 | 2010-03-11 | Q P Corp | Skin improvement agent for oral, food containing the same, and method for improving skin |
JP2011132161A (en) * | 2009-12-24 | 2011-07-07 | Lion Corp | Growth hormone secretion promoter |
WO2012121140A1 (en) | 2011-03-04 | 2012-09-13 | ライオン株式会社 | Growth hormone secretion promoter |
EP2893931A1 (en) | 2011-03-04 | 2015-07-15 | Lion Corporation | Growth hormone secretagogue |
KR20190034693A (en) | 2011-03-04 | 2019-04-02 | 라이온 가부시키가이샤 | Growth hormone secretion promoter |
KR101501328B1 (en) * | 2011-12-28 | 2015-03-18 | 동의대학교 산학협력단 | Skin care Composition |
JP2014047168A (en) * | 2012-08-31 | 2014-03-17 | Lion Corp | Growth hormone secretion promoter |
CN103808931A (en) * | 2012-11-06 | 2014-05-21 | 江苏维赛科技生物发展有限公司 | Enzyme linked immunosorbent assay kit for detecting sulfadiazine and detection method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP4596304B2 (en) | 2010-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4596304B2 (en) | Growth hormone secretion promoting composition | |
JP2011511620A (en) | Amino acid and peptide products | |
JP2023110016A (en) | Bioconversion of oleuropein | |
CA2537647A1 (en) | Supplemental dietary composition for supporting muscle growth, recovery and strength | |
JP2012530067A (en) | Glycomacropeptide medical food for nutritional management of phenylketonuria and other metabolic disorders | |
WO2015194070A1 (en) | Composition with high content of cyclic dipeptide | |
JP4231208B2 (en) | Nutritional supplements derived from fermented milk for the prevention of osteoporosis | |
JP5592640B2 (en) | Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor | |
SG195569A1 (en) | Nutritional composition with anti-regurgitation properties | |
CN103221531A (en) | Bacterium lactobacillus helveticus having high proteolysis activity | |
CN109022323A (en) | A kind of Lactobacillus helveticus complexing agent and its preparation method and application | |
JP2023110015A (en) | Bioconversion of oleuropein | |
ES2357408T3 (en) | SYMBOLIC COMPOSITION AND ITS MANUFACTURING PROCEDURE. | |
JP5855375B2 (en) | Anti-fatigue composition | |
WO2005122798A1 (en) | Functional beverage composition for improving ability of learning, concentration and memory | |
ES2434691T3 (en) | Agent to promote adiponectin secretion and / or inhibit the decrease in adiponectin secretion | |
JP2007029020A (en) | Black vinegar health food and method for producing the same | |
JP2006342134A (en) | Medicine given by using ank-khak and method for producing the same | |
JP4673071B2 (en) | Iron-adsorptive polymer substance, iron-containing polymer substance, and production method thereof | |
JP3979543B2 (en) | Antiallergic agent and method for producing the same | |
CN104757655A (en) | Earthworm amino acid beverage and preparation method thereof | |
CN107518073A (en) | A kind of probiotics goat milk piece and preparation method thereof | |
JPWO2006093013A1 (en) | Serum cholesterol lowering material, method for producing the same, food composition and pharmaceutical composition having serum cholesterol lowering action | |
JP2006273744A (en) | Hypotensive material, its manufacturing method, food composition and pharmaceutical composition having hypotensive action | |
KR101802400B1 (en) | Processed salt containing lactobacillus gaba and the method for manufacturing processed salt containing lactobacillus gaba thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100330 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100715 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100907 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100909 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4596304 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131001 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |